OncoMatch/Clinical Trials/NCT05849129
Adjunctive Intravenous Ascorbic Acid for Advanced Non-Small Cell Lung Cancer
Is NCT05849129 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies Ascorbic acid for lung cancer.
Treatment: Ascorbic acid — This is a two arm RCT evaluating the effect of intravenous vitamin C versus placebo in patients with incurable non-small cell lung cancer. Participants in both arms will be receiving platinum doublet chemotherapy with or without concurrent immunotherapy as standard care. We plan to enroll 90 patients over 5 years.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Non-Small Cell Lung Carcinoma
Small Cell Lung Cancer
Disease stage
Required: Stage IIIB, IV
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Cannot have received: cytotoxic chemotherapy
Previously undergone cytotoxic chemotherapy or immunotherapy within 12 months prior to randomization
Cannot have received: immunotherapy
Previously undergone cytotoxic chemotherapy or immunotherapy within 12 months prior to randomization
Cannot have received: IVC
Previously received IVC within 6 months prior to randomization
Lab requirements
Kidney function
egfr >= 45 ml/min
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT05849129 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
What disease stage is eligible?
Stage IIIB or IV is required.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify